Abstract:During evolution, the ability of many organisms to synthesize vitamin D photochemically represented, and still represents, a major driving factor for the development of life on earth. In humans because not more than 10-20% of the requirement of vitamin D can be satisfied by the diet (under most living conditions in the US and Europe), the remaining 80-90% need to be photochemically synthesized in the skin through the action of solar or artificial ultraviolet-B (UV-B) radiation. The skin is a key organ of the human body's vitamin D endocrine system (VDES), representing both the site of vitamin D synthesis and a target tissue for biologically active vitamin D metabolites. Human keratinocytes contain the enzymatic machinery (CYP27B1) for the synthesis of the biologically most active natural vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), representing an autonomous vitamin D3 pathway. Cutaneous production of 1,25(OH)2D3 may mediate intracrine, autocrine and paracrine effects on keratinocytes and on neighboring cells. Many skin cells (including keratinocytes, sebocytes, fibroblasts, melanocytes, macrophages and other skin immune cells) express the vitamin D receptor (VDR), an absolute pre-requisite for exerting genomic effects of 1,25(OH)2D3 and analogs. The VDR is a member of the superfamily of trans-acting transcriptional regulatory factors, which also contains the steroid and thyroid hormone receptors as well as the retinoid-X receptors (RXR) and retinoic acid receptors (RAR). A large body of evidence, including cDNA microarray analyses of mRNAs, indicates that as many as 500-1000 genes may be controlled by VDR ligands that regulate a broad variety of cellular functions including growth, differentiation, and apoptosis. Clinical and laboratory investigations, including the observation that 1,25(OH)2D3 is very effective in inducing the terminal differentiation and in inhibiting the proliferation of cultured human keratinocytes have resulted in the use of 1,25(OH)2D3 and analogs for the treatment of psoriasis. Focussing on the UV-induced cutaneous synthesis of vitamin D, this review gives an update on the relevance of the VDES and of UV radiation for the management of psoriasis and other inflammatory skin diseases.

Research Status of Vitamin D and its Derivatives on Psoriasis Treatment

Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy

Challenge and perspective: the relevance of ultraviolet (UV) radiation and the vitamin D endocrine system (VDES) for psoriasis and other inflammatory skin diseases

Vitamin D, omega-3 polyunsaturated fatty acids, antioxidants in the treatment of psoriasis

Vitamin D and the Pathophysiology of Inflammatory Skin Diseases

Targeting VEGF/VEGFR in the Treatment of Psoriasis.

The Role of VD/VDR Signaling Pathway in Autoimmune Skin Diseases

The Expression of Vitamin D Receptor on Peripheral Blood Mononuclear Cells in Patients with Psoriasis

Efficacy and safety of vitamin D supplementation on psoriasis: A systematic review and meta-analysis

VDR Gene Polymorphisms Are Associated with the Clinical Response to Calcipotriol in Psoriatic Patients

Using a Topical Formulation of Vitamin D for the Treatment of Vitiligo: A Systematic Review

Role Of Vegf Receptors In Normal And Psoriatic Human Keratinocytes: Evidence From Irradiation With Different Uv Sources

Advances in the Application of Natural Products and the Novel Drug Delivery Systems for Psoriasis

The Vitamin D3 Pathway in Human Skin and its Role for Regulation of Biological Processes

The role of vitamin D in the prevention of pathology associated with psoriasis and metabolic syndrome

The Effect of Phototherapy on Systemic Inflammation Measured with Serum Vitamin D-Binding Protein and hsCRP in Patients with Inflammatory Skin Disease

Promising strategies in natural products treatments of psoriasis-update

Vitamin D Analogs: Mechanism of Action and Therapeutic Applications

Clinical Value of Vitamin D, Trace Elements, Glucose, and Lipid Metabolism in Diagnosis and Severity Evaluation of Psoriasis

‘Psoriasis�1’ reduces T‐lymphocyte‐mediated inflammation in patients with psoriasis by inhibiting vitamin�D receptor‐mediated STAT4 inactivation

Vascular Endothelial Growth Factor A VEGFA Inhibition: An Effective Treatment Strategy for Psoriasis